Cartalax Dosage: Community Protocols Explained

Cartalax has no clinical-trial-established human dose. The published research is preclinical — cell-culture and gene-expression studies, mostly from Russian laboratories — so every protocol circulating online is community convention extrapolated from lab work and general peptide-handling habits, not a validated regimen. This guide reports those community figures honestly and shows the reconstitution math behind them.

Research-context information only. Cartalax (the AED tripeptide) is an unapproved research compound. It has not been evaluated by the FDA for any use, and human clinical data is limited to absent. Doses and protocols below come from vendor listings and self-reported community sources, not controlled trials. This article reports what is documented, not what should be done. Possession or use of research compounds may be restricted in your jurisdiction. Consult a licensed physician for personal medical decisions.

Cartalax is a short synthetic peptide bioregulator — the tripeptide Ala-Glu-Asp (AED) — from the Khavinson family of "peptide bioregulators." It has been studied for effects on chondrocyte and stem-cell gene expression related to cartilage and connective tissue. Below: the community-reported dosing landscape, the reconstitution math, and an honest read on how thin the evidence is.

Quick Reference: Community-Reported Protocol

No trial dose exists. Unlike peptides with published Phase 2 protocols, Cartalax has only preclinical cell-culture data behind it. The figures above describe what community sources do, not what evidence supports. For the full profile and vendor pricing, see our Cartalax peptide page.

Cycling Details

Community sources describe Cartalax the way the older Khavinson bioregulators were used clinically in Russia — as short, repeated low-dose courses (often 10-20 days) rather than continuous daily dosing. The original rationale, drawn from the bioregulator literature, is that short peptides act as transient signals to gene-expression machinery rather than agents needing steady blood levels (Khavinson & Anisimov, 2009). There is no controlled human data establishing an optimal cycle length, so this is convention, not evidence.

Routes of Administration

Subcutaneous injection is the route community protocols describe. Some bioregulator products are also sold in sublingual/oral-mucosal formats. No published human trial defines a route for Cartalax specifically.

• Sites: Community protocols describe subcutaneous injection into the abdomen, thigh, or other areas with adequate subcutaneous fat, rotating sites across courses
• Volume: Small — at 10 mg/mL even a 1 mg dose is only 0.1 mL
• Note: Because the community dose range is low and uncertain, many users dilute generously so small doses are measurable

Reconstitution Quick Reference

Math: 20 mg / 2 mL = 10 mg/mL. For 1 mg: 1 / 10 = 0.1 mL = 10 units on a 100-unit insulin syringe. For a 0.2 mg (200 mcg) dose at 10 mg/mL, that is just 2 units — which is why many community sources dilute further for measurable volumes.

Community protocols describe swirling gently (not shaking), refrigerating at 2–8°C, and using within 28 days. For the full step-by-step walkthrough, see the Cartalax Reconstitution Guide.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

This is the section that matters most for Cartalax, because the honest answer is: the dose numbers do not come from human trials.

The published evidence is preclinical. The strongest Cartalax-relevant study examined the AED peptide's effect on gene expression in aging human mesenchymal stem cells, where it raised IGF1 gene expression several-fold in cell culture (Ashapkin et al., 2020). A 2023 review summarized AED among peptides studied for chondrogenic (cartilage-forming) stem-cell regulation (Linkova et al., 2023). Both are cell-culture / mechanistic studies — neither establishes a human dose.

Community doses are extrapolated. The low-dose, short-course pattern circulating online is borrowed from how the original Khavinson tissue bioregulators were used, scaled by analogy and general peptide-handling convention. That is a reasonable starting point for the community, but it is not a tested protocol.

Why this matters: Peptides like ARA-290 or BPC-157 have a specific trial dose to point to. Cartalax does not — anyone presenting a precise "optimal" Cartalax dose as established fact is overstating the evidence.

Stacking Protocols

There is no human trial data on Cartalax stacks. Community sources sometimes pair it with other Khavinson bioregulators or with better-studied repair peptides, on a theoretical "different mechanisms" rationale.

These reflect community theory, not validated combinations.

Side Effects & Safety

• Limited safety data — there is no published human safety dataset for Cartalax specifically. Community reports describe it as well tolerated at low doses, but that is anecdote, not a safety profile.
• Injection-site reactions — the most commonly mentioned community-reported event (mild redness or irritation), consistent with other subcutaneous peptides.
• Unknown long-term effects — no long-term human exposure data exists.

The short-peptide bioregulator class has a generally benign profile in the preclinical literature, but absence of reported harm in cell-culture work is not the same as demonstrated human safety.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (100 units = 1 mL). The conversion depends on your chosen dilution.

Reconstitution A: 20 mg vial + 2 mL BAC water (10 mg/mL)

Reconstitution B: 20 mg vial + 4 mL BAC water (5 mg/mL) — more dilute, so low doses draw at larger, easier-to-read volumes.

These conversions report how community dilution math is described. They are not a recommended dosing schedule — no validated schedule exists.